Showing 991-1000 of 18563 results for "".
Ongoing Clinical Trials in AML With Menin Inhibitors
https://reachmd.com/programs/cme/ongoing-clinical-trials-in-aml-with-menin-inhibitors/36185/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Precision Starts Before Birth: Reimagining Fetal Care Through FcRn Immune Modulation
https://reachmd.com/programs/cme/Precision-Starts-Before-Birth-Reimagining-Fetal-Care-Through-FcRn-Immune-Modulation/37099/Explore FcRn inhibition as a preventive strategy for HDFN and FNAIT, with focus on ongoing trials including AZALEA and FREESIA.Case Review: Can You Crack This IBD Case?
https://reachmd.com/programs/cme/case-review-can-you-crack-this-ibd-case/51484/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
https://reachmd.com/programs/acc-action-center/no-improvements-in-cv-outcomes-at-90-days-with-human-apoa-1-infusions-post-mi/24288/ACC.24 - Michael Gibson shares the results of the AEGIS-II trial, in which infusions of human ApoA-1 - the building block of HDL-c - with CSL112 in the first month after an MI did not improve CV mortality, MI or stroke at 90 days.Improving Preventive Care of Patients With Hepatic Encephalopathy: Navigating the Subtleties and Beyond
https://reachmd.com/programs/cme/improving-preventive-care-of-patients-with-hepatic-encephalopathy-navigating-the-subtleties-and-beyond/36305/Learn how PCPs can identify early signs of hepatic encephalopathy to support timely diagnosis and clinical management.Echocardiographic workup for HCM – making the diagnosis and evaluation of cardiac function
https://reachmd.com/programs/cme/Echocardiographic-workup-for-HCM-making-the-diagnosis-and-evaluation-of-cardiac-function/32699/Three HCM experts discuss the role of echocardiography and other imaging techniques in the diagnosis and treatment of HCM.Immunotherapy Advances in Squamous Cell Anal Carcinoma: A New Standard of Care
https://reachmd.com/programs/project-oncology/immunotherapy-advances-in-squamous-cell-anal-carcinoma-a-new-standard-of-care/34983/Recent updates are redefining treatment expectations for squamous cell carcinoma of the anal canal, with immunotherapy now playing a central role. In fact, pivotal data from the phase 3 POD1UM-303 trial led to the FDA approval of retifanlimab in combination with carboplatin and paclitaxel, which isBeyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity
https://reachmd.com/programs/cme/beyond-the-horizon-in-multiple-myeloma-harnessing-novel-celmod-mechanisms-for-increased-antimyeloma-activity/35916/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityManaging Adverse Events Associated With Menin Inhibitors
https://reachmd.com/programs/cme/managing-adverse-events-associated-with-menin-inhibitors/36182/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Interpreting Test Results and Making the Treatment Decision Within the MDT
https://reachmd.com/programs/medical-industry-feature/interpreting-test-results-and-making-the-treatment-decision-within-the-mdt/13923/What is the pathologist’s role within the MDT in interpreting the test results and supporting the oncologist in treatment decision-making?